SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): April 18, 2008 (April 16,
2008)
CHEMBIO
DIAGNOSTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
5.03 AMENDMENTS
TO ARTICLES OF INCORPORATION OR BYLAWS, CHANGE IN FISCAL
YEAR.
On
April
17, 2008, the Board of Directors of Chembio Diagnostics, Inc.
amended the Company's bylaws to permit the electronic distribution
and
receipt of proxy materials as permitted by regulations adopted by the Securities
and Exchange Commission now or in the future.
ITEM
7.01. REGULATION
FD DISCLOSURE.
On
April
16, 2008, the Company issued a press release titled “Chembio Signs Exclusive
DPP™ Development Agreement with Bio-Rad Laboratories, Inc.” A copy of
the press release is furnished herewith as Exhibit 99.1.
ITEM
9.01. FINANCIAL STATEMENTS AND EXHIBITS
Exhibits.
|
3
|
New
Section 8 of Article I of the Bylaws for Chembio Diagnostics,
Inc.
|
|
99.1
|
Press
Release titled “Chembio Signs Exclusive DPP™
Development Agreement with Bio-Rad Laboratories, Inc.” issued April
16, 2008.
|
* * * * *
In
accordance with General Instruction B.2 of Form 8-K, the information in Item
7.01 of this Current Report on Form 8-K shall not be deemed “filed” for the
purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it
be
deemed incorporated by reference in any filing. This Current Report
on Form 8-K does not constitute a determination of whether any information
included herein is material.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: April
18,
2008 Chembio
Diagnostics, Inc.
By: /s/
Lawrence A.
Siebert
Lawrence
A.
Siebert
Chief
Executive Officer